Stock market analyst Hemant Kale of Maia Financial Services has maintained 'hold' rating on Ranbaxy Laboratories Limited stock to achieve a target of Rs 650.

According to analyst, the said target can be bought with a stop loss of Rs 570.

Today, the stock of the company opened at Rs 615 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 620.55 and a low of Rs 364.20 on BSE.

Current EPS & P/E ratio stood at 27.74 and 22.34 respectively.

During the July-September quarter, Ranbaxy's shares continued to perform brilliantly.

The share price gained 35%during the said period as against 12% increase of the Sensex.

During the last one year, Ranbaxy's scrip gained 57%, though there were no remarkable progressions to push its value in recent months.

Ranbaxy's domestic biz surged 14.8%, as per market research firm ORG as against a 20.4%growth for the entire domestic industry.

Hemant Bakhru, an analyst with brokerage firm CLSA, stated, "The company had recently won exclusive rights to sell the generic version of Aricept (Alzhiemer drug) for six months in the US. The company has also been having something or other every quarter to push up its sales. Further, some resolutions on the US Food and Drug Administration (the US regulator front are expected. All these are helping the stock."

Ranbaxy Laboratories Limited is the country's biggest pharmaceutical firm.

Set up in the year 1961, Ranbaxy exports its products to 125 nations with ground operations in 46 and manufacturing plants in seven nations.